This article talks about advancing thalassemia pre and treatment in Thailand.
Sponsored Content by BGI GenomicsAug 15 2023Reviewed by Olivia Frost On July 18th, a Memorandum of Understanding was signed between BGI Genomics, Faculty Of Medicine Siriraj Hospital at Mahidol University, Bangkok Genomics Innovation Public Company , and Hemogen Hong Kong Alpha Technology, Ltd.
Thailand faces a significant challenge with the prevalence of Thalassemia and sickle-cell anemia, causing hemoglobinopathies to emerge as a pressing public health issue. Statistical data reveals that 30-40% of the Thai population carries the Thalassemia gene. The Thalassemia gene testing kit, utilizing high-throughput sequencing technology, can simultaneously identify hemoglobinopathies such as Thalassemia and sickle-cell anemia.
This Memorandum of Understanding outlines the establishment of a long-term strategic partnership among the four parties, aiming to collaborate on the prevention, screening, diagnosis, and treatment of Thalassemia. Given its high prevalence in Thailand, Thalassemia places significant strain on the national healthcare system.
Mahidol University stands as Thailand's oldest institution for higher education, tracing its origins back to 1888 when it emerged as the Royal College of Physicians. BGI Genomics has executed several thalassemia genetic screening initiatives within China. Looking ahead, the company envisions deeper collaboration with stakeholders in Thailand, with the shared goal of propelling genetic technology to serve the well-being of the Thai populace.